Ask a gastroenterologist why a biologic stopped working. You will often get the same answer: the patient started making antibodies against the drug. It is one of the least glamorous problems in inflammatory bowel disease, and one of the most consequential. Anti-drug antibodies are the quiet tax on nearly every biologic we use. So the […]
Anti-Drug Antibodies: The Quiet Tax on Every IBD Biologic Read More »
Most drug targets earn their reputation in one disease and stay there. TL1A is not behaving that way. A target that made its name in inflammatory bowel disease is now being pushed well beyond it. Think rheumatoid and psoriatic arthritis, hidradenitis suppurativa, atopic dermatitis, and, most tellingly, fibrotic disease. TL1A beyond IBD is the part
TL1A Beyond IBD: What Happens When a Gut Target Goes Systemic Read More »
For all the sophistication in the TL1A pipeline, every one of these drugs shares a low-tech limitation. It is an antibody, and antibodies get injected. That is fine for many patients, but the irony is worth sitting with. We are building exquisitely targeted therapies for a disease of the gut. Yet we deliver almost none
Oral Drug Delivery in IBD: Why the Best New Drugs Still Come as Injections Read More »
Inflammatory bowel disease has a stubborn ceiling. Even the best biologics put only a minority of patients into durable, steroid-free remission. And every new mechanism eventually plateaus at a similar wall. That is the problem TL1A bispecific antibodies are built to solve. Instead of blocking one node in the inflammatory cascade, they engage two at
TL1A Bispecifics: The Race to Break the IBD Efficacy Ceiling Read More »